Here's that latest bit, from the beaches at Barcelonetta (in the former Summer Olympics village) -- via the expert coverage provided by Fierce staffers:
. . .Partners Daiichi Sankyo and Merck & Co. are sharing new phase 2 data for their investigational antibody-drug conjugate, findings the partners think will help score accelerated approval in pretreated small cell lung cancer (SCLC).
“The important take-home message is that this is our registrational trial for the first approval of the drug I-DXd,” Daiichi’s R&D head Ken Takeshita, M.D., told Fierce Biotech Friday.
The primary analysis reveals an objective response rate (ORR) of 48.2% among 137 patients receiving 12 mg/kg of I-DXd, also known as ifinatamab deruxtecan, according to a late-breaking presentation shared at this year’s World Conference on Lung Cancer in Barcelona, Spain.
The ORR is down slightly from the rate seen in an earlier stage of the trial, in which the B7-H3-directed ADC was tied to a 54.8% ORR among 42 patients on the same dose level. Daiichi and Merck reported results from the dose-optimization stage of the phase 2 trial, dubbed IDeate-Lung01, a year ago. . . .
Now you know -- onward, smiling. . . ever, smiling.
नमस्ते
No comments:
Post a Comment